Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Bullish On Januvia Prospects Despite Soft First Quarter Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharma company sees plenty of potential for its top-selling drug even as its sales came in weak during the first quarter. Meanwhile, Merck welcomes its new head of R&D and the potential for change.

Advertisement

Related Content

Emerging Markets Earnings Roundup: Pfizer And Merck (Part 5)
Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split
Merck And Pfizer Make A Late Play For The Diabetes Market
Avandia RECORD Study Re-Analysis To Get FDA Committee Scrutiny
J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel